VBI Vaccines Inc. (NASDAQ:VBIV) Expected to Post Quarterly Sales of $130,000.00

Wall Street analysts expect VBI Vaccines Inc. (NASDAQ:VBIVGet Rating) to announce sales of $130,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for VBI Vaccines’ earnings. The highest sales estimate is $160,000.00 and the lowest is $100,000.00. VBI Vaccines reported sales of $300,000.00 in the same quarter last year, which would suggest a negative year-over-year growth rate of 56.7%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that VBI Vaccines will report full-year sales of $5.74 million for the current fiscal year, with estimates ranging from $4.00 million to $8.01 million. For the next fiscal year, analysts forecast that the company will report sales of $29.03 million, with estimates ranging from $20.60 million to $43.08 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for VBI Vaccines.

VBI Vaccines (NASDAQ:VBIVGet Rating) last released its earnings results on Monday, March 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). VBI Vaccines had a negative return on equity of 42.79% and a negative net margin of 11,054.36%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.14 million.

Several equities research analysts have commented on VBIV shares. Raymond James dropped their target price on VBI Vaccines from $9.00 to $6.00 and set a “strong-buy” rating on the stock in a report on Tuesday, March 8th. Zacks Investment Research upgraded VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Tuesday, April 5th. Finally, Jefferies Financial Group began coverage on VBI Vaccines in a research note on Thursday, December 30th. They issued a “buy” rating and a $6.00 price target for the company.

VBI Vaccines stock traded up $0.09 during mid-day trading on Wednesday, hitting $1.67. The company had a trading volume of 1,420,723 shares, compared to its average volume of 2,297,321. The company has a current ratio of 4.00, a quick ratio of 3.92 and a debt-to-equity ratio of 0.20. The stock’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $2.23. VBI Vaccines has a 12 month low of $1.21 and a 12 month high of $4.31. The company has a market capitalization of $429.70 million, a PE ratio of -6.19 and a beta of 1.97.

A number of institutional investors have recently bought and sold shares of VBIV. PNC Financial Services Group Inc. increased its position in VBI Vaccines by 433.0% during the third quarter. PNC Financial Services Group Inc. now owns 8,448 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 6,863 shares during the last quarter. Wealth Alliance Advisory Group LLC purchased a new stake in VBI Vaccines during the fourth quarter valued at $28,000. WINTON GROUP Ltd purchased a new stake in VBI Vaccines during the third quarter valued at $31,000. Mackenzie Financial Corp purchased a new stake in VBI Vaccines during the third quarter valued at $34,000. Finally, Point72 Hong Kong Ltd purchased a new stake in VBI Vaccines during the fourth quarter valued at $43,000. Institutional investors own 43.61% of the company’s stock.

About VBI Vaccines (Get Rating)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

Further Reading

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.